New Frontiers in the Medical Therapy of Hepatocellular Carcinoma

Keyphrases

• Hepatocellular Carcinoma 100%
• Medical Therapy 100%
• New Frontiers 100%
• Immune Checkpoint Inhibitors 100%
• Therapeutic Strategies 20%
• Monotherapy 20%
• Adjuvant Therapy 20%
• Early Disease 20%
• Antiangiogenic Agents 20%
• New Therapeutics 20%
• Cancer Mortality 20%
• Rapidly Evolving 20%
• Liver Disease 20%
• Frontline Therapy 20%
• Neoadjuvant Therapy 20%
• Tyrosine Kinase Inhibitor 20%
• Disease Management 20%
• Unresectable Hepatocellular Carcinoma 20%
• Cancer Causes 20%
• Therapeutic Advances 20%
• Chemosensitivity 20%
• Patient Stratification 20%
• Ongoing Trials 20%
• Advanced Hepatocellular Carcinoma 20%
• Phase III Clinical Trial 20%
• Primary Liver Cancer 20%
• Atezolizumab Plus Bevacizumab 20%
• Sequence of Therapy 20%
• Treatment Challenges 20%
• Dual Checkpoint Inhibition 20%
• Systemic Management 20%

Medicine and Dentistry

• Combination Therapy 100%
• Hepatocellular Carcinoma 100%
• Immune Checkpoint Inhibitor 83%
• Clinical Trial 16%
• Malignant Neoplasm 16%
• Liver Disease 16%
• Immunotherapy 16%
• Adjuvant Therapy 16%
• Angiogenesis Inhibitor 16%
• Monotherapy 16%
• Disease Management 16%
• Tyrosine-Kinase Inhibitor 16%
• Liver Tumor 16%
• Chemosensitivity 16%
• Neoadjuvant Therapy 16%
• Bevacizumab 16%
• Atezolizumab 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Liver Cell Carcinoma 100%
• Combination Therapy 100%
• Immune Checkpoint Inhibitor 83%
• Malignant Neoplasm 16%
• Clinical Trial 16%
• Monotherapy 16%
• Liver Disease 16%
• Liver Tumor 16%
• Angiogenesis Inhibitor 16%
• Protein Tyrosine Kinase Inhibitor 16%
• Immunotherapy 16%
• Bevacizumab 16%
• Atezolizumab 16%
• Diseases 16%